Capital Fund Management (CFM)’s Emergent Biosolutions EBS Stock Holding History

Capital Fund Management (CFM)’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-91,917	Closed	-$676K	–	1977
2023 Q2	$676K	Buy	+91,917	New	+$852K	﹤0.01%	1510
2022 Q4	–	Sell	-70,498	Closed	-$1.48M	–	1449
2022 Q3	$1.48M	Sell	70,498 -16,705	-19%	-$465K	0.01%	948
2022 Q2	$2.71M	Buy	87,203 +48,773	+127%	+$1.67M	0.02%	726
2022 Q1	$1.58M	Buy	+38,430	New	+$1.69M	0.01%	1033
2021 Q3	–	Sell	-24,219	Closed	-$1.53M	–	1582
2021 Q2	$1.53M	Buy	+24,219	New	+$1.56M	0.01%	1038
2020 Q4	–	Sell	-21,726	Closed	-$2.24M	–	1343
2020 Q3	$2.24M	Buy	+21,726	New	+$2.34M	0.03%	603
2016 Q3	–	Sell	-15,600	Closed	-$439K	–	1614
2016 Q2	$439K	Buy	+15,600	New	+$612K	﹤0.01%	1214

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Capital Fund Management (CFM)'s EBS Position: Q3 2023 in Review

Capital Fund Management (CFM) sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 91,917 shares — an estimated $676K sold.

Capital Fund Management (CFM) first reported a position in EBS in Q2 2016 and held it in 7 quarters. The position peaked at $2.71M in Q2 2022. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

Capital Fund Management (CFM) reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
Capital Fund Management (CFM) sold 91,917 Emergent Biosolutions shares in Q3 2023, an estimated $676K.
Capital Fund Management (CFM) first reported a position in Emergent Biosolutions in Q2 2016 and held it in 7 quarters.
Capital Fund Management (CFM)'s Emergent Biosolutions position peaked at $2.71M in Q2 2022.
162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2023, filed 14 Nov 2023.